OBJECTIVE:

To assess the impact of oral cannabidiol ( CBD) administration in addition to traditional antiepileptic remedy on seizure frequency in dogs with idiopathic epilepsy.

Design and style:

Randomized blinded controlled clinical trial.

ANIMALS:

26 client-owned dogs with intractable idiopathic epilepsy.

PROCEDURES:

Dogs had been randomly assigned to a CBD (n = 12) or placebo (14) group. The CBD group received CBD-infused oil (two.five mg/kg [1.1 mg/lb], PO) twice everyday for 12 weeks in addition to current antiepileptic remedies, and the placebo group received noninfused oil beneath the identical circumstances. Seizure activity, adverse effects, and plasma CBD concentrations had been compared among groups.

Final results:

two dogs in the CBD group created ataxia and had been withdrawn from the study. Right after other exclusions, 9 dogs in the CBD group and 7 in the placebo group had been incorporated in the evaluation. Dogs in the CBD group had a important (median modify, 33%) reduction in seizure frequency, compared with the placebo group. Having said that, the proportion of dogs thought of responders to remedy (≥ 50% reduce in seizure activity) was comparable among groups. Plasma CBD concentrations had been correlated with reduction in seizure frequency. Dogs in the CBD group had a important boost in serum alkaline phosphatase activity. No adverse behavioral effects had been reported by owners.

CONCLUSIONS AND CLINICAL RELEVANCE:

Despite the fact that a important reduction in seizure frequency was accomplished for dogs in the CBD group, the proportion of responders was comparable among groups. Provided the correlation among plasma CBD concentration and seizure frequency, more analysis is warranted to identify no matter if a larger dosage of CBD would be productive in lowering seizure activity by ≥ 50%.